Kriya Therapeutics: Gene Therapy. Redefined.
Kriya is targeting diseases that impact millions of people worldwide and represent areas of high unmet need. We target validated biological pathways with innovative gene therapy approaches …
Careers: Future of Gene Therapy - Kriya Therapeutics
Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. From California to North …
Our Team: Leaders in Gene Therapy - Kriya Therapeutics
Kriya’s team of gene therapy pioneers and biopharma veterans is building a pipeline to address common diseases.
Metabolic Disease: Gene Therapy for Diabetes and NASH - Kriya …
Kriya’s KRIYA-839, an adeno-associated virus (AAV)-based gene therapy, is a groundbreaking approach to restoring insulin production and enhancing glucose metabolism in type 1 diabetes.
Kriya Presents Data at the 2025 Association for Research in Vision …
Kriya is developing KRIYA-825, a potential one-time gene therapy for Geographic Atrophy (GA) that expresses a fusion protein designed to inhibit the activity of complement C3 and C5, with …
Pipeline - Kriya Therapeutics
Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology.
Kriya Announces Thirteen Presentations at the American Society of …
Apr 29, 2025 · Kriya is a biopharmaceutical company developing gene therapies to address chronic diseases affecting millions of people around the world. With operations in Research …
Newsroom: Gene Therapy Pipeline News - Kriya Therapeutics
Jun 18, 2024 · Kriya shares the latest news on our pipeline of life-changing gene therapies to address common diseases.
Neurology: Gene Therapy for Trigeminal Neuralgia - Kriya …
Kriya is developing KRIYA‑748, a potential one-time gene therapy for trigeminal neuralgia that expresses a chemogenetically-gated ion channel and is designed to be administered as an …
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene ...
Sep 12, 2024 · KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor …